A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. Quantinuum was created in 2021 when industrial manufacturing juggernaut Honeywell spun ...

Since then, Odyssey has had no problems bringing in the megarounds. As well as the $218 million that the company launched ...

While GLP-1s like Ozempic and Wegovy are being widely prescribed for weight loss, doctors currently do not have a way to ...

GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...

The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle ...

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data ...

In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future ...

Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms.

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...

The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse ...

Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...